Silence Therapeutics

LONDON, January 9, 2012/PRNewswire-FirstCall/ –

- Third collaboration to investigate the potential application of Silence’s proprietary RNAi delivery technologies in the development of novel microRNA-based therapeutics

Silence Therapeutics signs collaboration with miRagen TheapeuticsSilence Therapeutics plc (AIM: SLN) (“Silence”), a leading RNA interference (RNAi) therapeutics company, announces that it has signed an agreement with miRagen Therapeutics, Inc. (“miRagen”), to assess the delivery potential of Silence’s proprietary DBTC delivery system with miRagen’s novel microRNA- (miRNA-) based therapeutics. MiRagen is a pre-clinical stage biopharmaceutical company founded to develop innovative miRNA-based therapeutics for the treatment of cardiovascular and muscle disease.

Under the terms of the agreement, miRagen will provide Silence with specific miRNA sequences, which Silence will formulate with its proprietary DBTC delivery system in order to develop multiple candidate drugs. MiRagen will undertake in vitro and in vivo studies of the candidate drugs developed under the agreement and select lead candidates for further evaluation. Financial terms of the collaboration are not disclosed.

DBTC is a proprietary RNAi delivery system developed by Silence. It is a novel lipid-based formulation that functionally delivers short interfering RNA (siRNA) to liver endothelial cells, hepatocytes and other liver cell types with high efficiency.

Thomas Christely, Chief Executive Officer of Silence Therapeutics, said: “We are delighted to be collaborating with miRagen. This is the third collaboration that [click to continue…]

{ 0 comments }

Collaboration to investigate potential application of Silence’s novel AtuPLEX(TM)and DBTC delivery technologies in the development of novel microRNA therapeutics targeting cancer

LONDON, October 24, 2011/PRNewswire-FirstCall/ –

Silence Therapeutics plc (AIM: SLN) (“Silence”), a leading RNA interference (RNAi) therapeutics company, today announced that it has entered into an agreement with Mirna Therapeutics Inc. (“Mirna”), a biopharmaceutical company pioneering microRNA-based therapeutics for cancer, to assess the delivery capabilities of Silence’s proprietary AtuPLEX(TM) and DBTC delivery systems for Mirna’s novel microRNAs.

Under the terms of the agreement, Mirna will provide Silence with specific miRNA sequences, which Silence will formulate with its AtuPLEX(TM) and DBTC delivery systems in order to develop multiple candidate drugs. Mirna will undertake in vitro and in vivo studies of the candidate drugs developed under the agreement and select lead candidates for further evaluation. Financial terms of the deal were not disclosed.

Thomas Christely, Chief Executive Officer of Silence Therapeutics, said: “We are delighted to be collaborating with Mirna. This is our second collaboration exploring the use of Silence’s delivery technologies to deliver microRNAs. However, it is [click to continue…]

{ 0 comments }